The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results from phase I/II study of NY-ESO-1-specific TCR gene-transduced T cell therapy (TBI-1301, mipetresgene autoleucel) in patients with advanced synovial sarcoma.
 
Akira Kawai
Honoraria - Bayer; Daiichi Sankyo; Eisai; Novartis; Taiho Pharmaceutical
 
Mikiya Ishihara
Honoraria - AstraZeneca/Daiichi Sankyo; Chugai Pharma; Eisai; Lilly; MSD; Ono Pharmaceutical
 
Tomoki Nakamura
No Relationships to Disclose
 
Shigehisa Kitano
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Janssen; Lilly Japan; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; GlaxoSmithKline; ImmuniT Research Inc.; Ono Pharmaceutical; Rakuten Medical; Sumitomo Dainippon Pharma; United Immunity
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim; Boehringer Ingelheim (Inst); Chugai Pharma; Chugai Pharma (Inst); Daiichi Sankyo; Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Loxo/Lilly (Inst); MSD (Inst); Ono Pharmaceutical; Ono Pharmaceutical (Inst); Pfizer (Inst); Takara Bio; Takeda (Inst)
 
Shintaro Iwata
Speakers' Bureau - Eisai; Novartis; Taiho Pharmaceutical
 
Kohichi Takada
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo Pharmaceutical; Eisai; Janssen; Lilly O.; Ono Pharmaceutical; Otsuka; Sanofi
 
Makoto Emori
No Relationships to Disclose
 
Koji Kato
Honoraria - Bristol-Myers Squibb; Celgene; Dainippon-Sumitomo; Janssen; Kyowa Kirin International; MSD; Mundipharma; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Celgene; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen; Novartis
Research Funding - Abbvie; Celgene; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen; Kyowa Kirin International; Novartis; Novartis; Ono Pharmaceutical; Takeda
 
Makoto Endo
Honoraria - Bayer
Consulting or Advisory Role - Eisai
Speakers' Bureau - Boehringer Ingelheim; Daiichi Sankyo; Eisai; Kyowa Kirin; Taiho Pharmaceutical; Teijin Ltd
Research Funding - AYUMI; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Taiho Pharmaceutical
 
Yoshihiro Matsumoto
No Relationships to Disclose
 
Shigeki Kakunaga
Research Funding - Daiichi Sankyo Pharmaceutical
 
Eiichi Sato
No Relationships to Disclose
 
Yoshihiro Miyahara
No Relationships to Disclose
 
Kunihiko Morino
Employment - Takara Bio
Stock and Other Ownership Interests - Takara Bio
 
Shinya Tanaka
Employment - Takara Bio; Takara Bio (I)
 
Shuichi Takahashi
Employment - Takara Bio
Stock and Other Ownership Interests - Takara Bio
 
Akihiko Matsumine
No Relationships to Disclose
 
Shinichi Kageyama
Stock and Other Ownership Interests - Kyowa Kirin
Consulting or Advisory Role - Ono Pharmaceutical; Otsuka Pharmaceuticals
Speakers' Bureau - Chugai Pharma
 
Takafumi Ueda
No Relationships to Disclose